S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.94 (+0.02%)
AAPL   172.11 (-0.69%)
MSFT   421.38 (-0.01%)
META   488.49 (-1.09%)
GOOGL   151.13 (+0.17%)
AMZN   180.58 (+0.42%)
TSLA   175.50 (-2.41%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   180.16 (+0.32%)
BABA   72.39 (+1.12%)
T   17.67 (+0.68%)
F   13.25 (+1.45%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   175.94 (-2.32%)
DIS   122.48 (+1.24%)
AMC   3.73 (-14.06%)
PFE   27.84 (+0.22%)
PYPL   66.99 (+0.63%)
XOM   116.31 (+1.17%)
S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.94 (+0.02%)
AAPL   172.11 (-0.69%)
MSFT   421.38 (-0.01%)
META   488.49 (-1.09%)
GOOGL   151.13 (+0.17%)
AMZN   180.58 (+0.42%)
TSLA   175.50 (-2.41%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   180.16 (+0.32%)
BABA   72.39 (+1.12%)
T   17.67 (+0.68%)
F   13.25 (+1.45%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   175.94 (-2.32%)
DIS   122.48 (+1.24%)
AMC   3.73 (-14.06%)
PFE   27.84 (+0.22%)
PYPL   66.99 (+0.63%)
XOM   116.31 (+1.17%)
S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.94 (+0.02%)
AAPL   172.11 (-0.69%)
MSFT   421.38 (-0.01%)
META   488.49 (-1.09%)
GOOGL   151.13 (+0.17%)
AMZN   180.58 (+0.42%)
TSLA   175.50 (-2.41%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   180.16 (+0.32%)
BABA   72.39 (+1.12%)
T   17.67 (+0.68%)
F   13.25 (+1.45%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   175.94 (-2.32%)
DIS   122.48 (+1.24%)
AMC   3.73 (-14.06%)
PFE   27.84 (+0.22%)
PYPL   66.99 (+0.63%)
XOM   116.31 (+1.17%)
S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.94 (+0.02%)
AAPL   172.11 (-0.69%)
MSFT   421.38 (-0.01%)
META   488.49 (-1.09%)
GOOGL   151.13 (+0.17%)
AMZN   180.58 (+0.42%)
TSLA   175.50 (-2.41%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   180.16 (+0.32%)
BABA   72.39 (+1.12%)
T   17.67 (+0.68%)
F   13.25 (+1.45%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   175.94 (-2.32%)
DIS   122.48 (+1.24%)
AMC   3.73 (-14.06%)
PFE   27.84 (+0.22%)
PYPL   66.99 (+0.63%)
XOM   116.31 (+1.17%)

Apellis Pharmaceuticals (APLS) Stock Price, News & Analysis

$58.54
+0.05 (+0.09%)
(As of 03:39 PM ET)
Today's Range
$56.82
$58.87
50-Day Range
$55.39
$71.73
52-Week Range
$19.83
$94.75
Volume
850,391 shs
Average Volume
1.56 million shs
Market Capitalization
$7.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$77.93

Apellis Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.87 Rating Score
Upside/​Downside
36.8% Upside
$77.93 Price Target
Short Interest
Bearish
8.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.27
Upright™ Environmental Score
News Sentiment
0.88mentions of Apellis Pharmaceuticals in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$22.36 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.36) to $1.09 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.65 out of 5 stars

Medical Sector

79th out of 939 stocks

Pharmaceutical Preparations Industry

30th out of 433 stocks

APLS stock logo

About Apellis Pharmaceuticals Stock (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

APLS Stock Price History

APLS Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments (APLS)
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals
APLS Mar 2024 56.000 put
APLS Mar 2024 59.000 call
APLS Mar 2024 50.000 put
APLS Mar 2024 69.000 call
APLS Mar 2024 58.000 put
APLS Mar 2024 62.000 put
APLS Mar 2024 90.000 call
See More Headlines
Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:APLS
Fax
N/A
Employees
702
Year Founded
2009

Price Target and Rating

Average Stock Price Target
$77.93
High Stock Price Target
$106.00
Low Stock Price Target
$54.00
Potential Upside/Downside
+35.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

Net Income
$-528,630,000.00
Net Margins
-133.34%
Pretax Margin
-132.76%

Debt

Sales & Book Value

Annual Sales
$396.59 million
Book Value
$1.64 per share

Miscellaneous

Free Float
111,538,000
Market Cap
$6.94 billion
Optionable
Optionable
Beta
0.90

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

APLS Stock Analysis - Frequently Asked Questions

Should I buy or sell Apellis Pharmaceuticals stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 3 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" APLS shares.
View APLS analyst ratings
or view top-rated stocks.

What is Apellis Pharmaceuticals' stock price target for 2024?

15 brokerages have issued 12-month price objectives for Apellis Pharmaceuticals' stock. Their APLS share price targets range from $54.00 to $106.00. On average, they expect the company's stock price to reach $77.93 in the next twelve months. This suggests a possible upside of 36.8% from the stock's current price.
View analysts price targets for APLS
or view top-rated stocks among Wall Street analysts.

How have APLS shares performed in 2024?

Apellis Pharmaceuticals' stock was trading at $59.86 at the beginning of 2024. Since then, APLS shares have decreased by 4.9% and is now trading at $56.95.
View the best growth stocks for 2024 here
.

Are investors shorting Apellis Pharmaceuticals?

Apellis Pharmaceuticals saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 10,590,000 shares, an increase of 5.3% from the February 29th total of 10,060,000 shares. Based on an average daily volume of 1,580,000 shares, the days-to-cover ratio is currently 6.7 days.
View Apellis Pharmaceuticals' Short Interest
.

When is Apellis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our APLS earnings forecast
.

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) released its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.73) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.73). The firm earned $146.38 million during the quarter, compared to analyst estimates of $143.34 million. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 178.60% and a negative net margin of 133.34%. The firm's revenue for the quarter was up 545.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.50) EPS.

What ETFs hold Apellis Pharmaceuticals' stock?
What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?

18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

When did Apellis Pharmaceuticals IPO?

Apellis Pharmaceuticals (APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.06%), Vanguard Group Inc. (7.92%), Jennison Associates LLC (2.76%), Octagon Capital Advisors LP (2.37%), Price T Rowe Associates Inc. MD (2.08%) and Price T Rowe Associates Inc. MD (2.08%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Caroline Baumal, Cedric Francois, David O Watson, Federico Grossi, James George Chopas, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Nur Nicholson, Pascal Deschatelets, Timothy Eugene Sullivan and Victoria L Brown.
View institutional ownership trends
.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Apellis Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Apellis Pharmaceuticals: APL DEL Holdings II LLC, APL DEL Holdings LLC, APL PRG I Corp., APL Sales I LLC, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., Apellis MA Securities Inc., Apellis Netherlands B.V., Apellis Switzerland GmbH, Apellis U.K. Limited, and Potentia Pharmaceuticals.
Read More
This page (NASDAQ:APLS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners